Antihyperglycemic, antihyperlipidemic, anti-inflammatory and adenosine deaminase-lowering effects of garlic in patients with type 2 diabetes mellitus with obesity

Diabetes, Metabolic Syndrome and Obesity

Volumn 6, Issue , 2013, Pages 49-56

  Kumar, Rahat ^a   Chhatwal, Simran ^a   Arora, Sahiba ^a   Sharma, Sita ^a   Singh, Jaswinder ^a   Singh, Narinder ^a   Bhandari, Vikram ^a   Khurana, Ashok ^a  

^a SRI GURU RAM DAS INSTITUTE OF MEDICAL SCIENCES AND RESEARCH   (India)

Author keywords

Allium sativum; C reactive protein; Metformin

Indexed keywords

ADENOSINE DEAMINASE; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HERBACEOUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LASUNA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; FASTING BLOOD GLUCOSE; FEMALE; GARLIC; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POSTPRANDIAL BLOOD GLUCOSE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 84872925873     PISSN: 11787007     EISSN: None     Source Type: Journal    
DOI: 10.2147/dmso.s38888     Document Type: Article

References (45)

1. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organization; 1999. Available from: http://www.who.int/diabetes/currentpublications/en/. Accessed December 14, 2012.
2. Ramchandran A, Snehalatha C, Vijay V. Burden of type 2 diabetes and its complications - the Indian scenario. Current Science. 2002;83: 1471-1476.
3. Cowie CC, Eberhardt MS, editors. Diabetes 1996: Vital Statistics. Alexandria: American Diabetes Association; 1996.
4. Davidson MB. Diabetes Mellitus: Diagnosis and Treatment, 3rd ed. New York: Churchill Livingstone; 1991.
5. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258): 405-412.
6. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes. 2002;51(4):1157-1165.
7. Lapice E, Maione S, Patti L, et al. Abdominal adiposity is associated with elevated C-reactive protein independent of BMI in healthy nonobese people. Diabetes Care. 2009;32(9):1734-1736.
8. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448-454.
9. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796-1808.
10. Duncan BB, Schmidt M, Pankow JS, et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes. 2003;52(7):1799-1805.
11. Prakash MS, Chennaiah S, Murthy YS, Anjaiah E, Rao SA, Suresh C. Altered adenosine deaminase activity in type 2 diabetes mellitus. JIACM. 2006;7:114-117.
12. Kurtul N, Pence S, Akarsu E, Kocoglu H, Aksoy Y, Aksoy H. Adenosine deaminase activity in the serum of type 2 diabetic patients. Acta Medica (Hradec Kralove). 2004;47(1):33-35.
13. De Fronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131(4):281-303.
14. Lima LM, Wiernsperger N, Kraemer-Aguiar LG, Bouskela E. Short-term treatment with metformin improves the cardiovascular risk profile in first-degree relatives of subjects with type 2 diabetes mellitus who have a metabolic syndrome and normal glucose tolerance without changes in C-reactive protein or fibrinogen. Clinics (Sao Paulo). 2009;64(5):415-420.
15. American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care. 2011;34 Suppl 1:S11-S61.
16. Caballero AE, Delgado A, Aguilar-Salinas CA, et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab. 2004;89(8):3943-3948.
17. Haffner S, Temprosa M, Crandall J, et al; Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes. 2005;54(5):1566-1572.
18. [No authors listed]. WHO Expert Committee on Diabetes Mellitus: second report. World Health OrganTech Rep Ser. 1980;646:1-80.
19. Agarwal KC. Therapeutic actions of garlic constituents. Med Res Rev. 1996;16(1):111-124.
20. Yeh YY, Yeh SM. Garlic reduces plasma lipids by inhibiting hepatic cholesterol and triacylglycerol synthesis. Lipids. 1994;29(3):189-193.
21. Melzig MF, Krause E, Franke S. Inhibition of adenosine deaminase activity of aortic endothelial cells by extracts of garlic (Allium sativum L.). Pharmazie. 1995;50(5):359-361.
22. Zeb I, Ahmadi N, Nasir K, et al. Aged garlic extract and coenzyme Q10 have favorable effect on inflammatory markers and coronary atherosclerosis progression: A randomized clinical trial. J Cardiovasc Dis Res. 2012;3(3):185-190.
23. Ide N, Lau BH. Garlic compounds minimize intracellular oxidative stress and inhibit nuclear factor-kappa b activation. J Nutr. 2001;131(Suppl 3):S1020-S1026.
24. Williams MJ, Sutherland WH, McCormick MP, Yeoman DJ, de Jong SA. Aged garlic extract improves endothelial function in men with coronary artery disease. Phytother Res. 2005;19(4):314-319.
25. Lasuna (capsule) [product information]. The Himalaya Drug Company; 2002. Available from: http://www.himalayahealthcare.com/products/lasuna.htm#d. Accessed January 5, 2013.
26. Trinder P. Determination of blood glucose using an oxidase peroxidase system with a non-carcinogenic chromogen. J Clin Pathol. 1969;22(2):158-161.
27. Allain C, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20(4):470-475.
28. Trinder P. Triglycerides estimation by GPO-PAP method. Ann Clin Biochem. 1996;6:24-27.
29. Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res. 1970;11(6):583-595.
30. Bairaktari ET, Seferiadis KI, Elisaf MS. Evaluation of methods for the measurement of low-density lipoprotein cholesterol. J Cardiovasc Pharmacol Therapeut. 2005;10(1):45-54.
31. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ. 1996;312(7038):1061-1065.
32. Giusti G, Galanti R. Adenosine deaminase. In: Bergmeyer HU, editor. Methods of Enzymatic Analysis, 2nd ed. New York: Academic Press Inc; 1974;2:1092-1099.
33. Jeppsson J, Kobold U, Barr J, et al; International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med. 2002;40(1):78-89.
34. NIH/NHLBI (National Institutes of Health, National Heart, Lung, and Blood Insitute). Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults. Bethesda: National Institutes of Health; 1998. Available from: http://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.htm. Accessed December 14, 2012.
35. Mannucci E, Monami M, Lamanna C, Adalsteinsson JE. Post-prandial glucose and diabetic complications: systematic review of observational studies. Acta Diabetol. 2012;49(4):307-314.
36. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333(9):550-554.
37. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. The Multicenter Study Group. N Eng J Med. 1995;333(9):541-549.
38. Ashraf R, Alam Khan R, Ashraf I. Effects of garlic on blood glucose levels and HbA1c in patients with type 2 diabetes mellitus. J Med Plants Res. 2011;5(13):2922-2928.
39. Sobenin IA, Nedosugova LV, Filatova LV, Balabolkin MI, Gorchakova TV, Orekhov AN. Metabolic effects of time-released garlic powder tablets in type 2 diabetes mellitus: the results of double-blinded placebo-controlled study. Acta Diabetol. 2008;45(1):1-6.
40. Robinson AC, Burke J, Robinson S, Johnston GD, Elkeles RS. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care. 1998;2(5):701-705.
41. Wulffelé MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Int Med. 2004;256(1):1-14.
42. Wu MS, Johnston P, Sheu WH, et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care. 1990;13(1):1-8.
43. Santen RJ, Willin PW 3rd, Fajans SS. Atherosclerosis in diabetes mellitus. Correlations with serum lipid levels, adiposity, and serum insulin level. Arch Intern Med. 1972;130(6):833-843.
44. Pradhan AD, Everett BM, Cook NR, Rifai N, Ridker PM. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. JAMA. 2009;302(11):1186-1196.
45. Koch HP, Jäger W, Hysek J, Körpert B. Garlic and onion extracts: in vitro inhibition of adenosine deaminase. Phytother Res. 1992;6(1):50-52.